Gland Pharma Ltd (GLAND) Q4FY26 Management Mirror - Mar-2026 Qtr
Revenue Growth
Management expects consolidated constant currency revenue growth of 12% to 13% for FY27 (excluding GLP-1 upside), transitioning from prior FY26 guidance of a minimum 12% to 13% growth (Dec'25 Qtr) and mid-teens growth (Sep'25 Qtr); additionally, the long-term organic target was reaffirmed at a 15% revenue CAGR over the next four years through FY30, with a major step-up anticipated in FY29 as complex products launch. [Status: Initiated]
4 more themes on the ELITE plan.